Walleye Capital LLC has recently announced that it has increased stake in Revelation Biosciences Inc (NASDAQ:REVB) by 26.60%. After grabbing 0.39 million shares, the institutional investor is now in possession of 82219.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.22% having worth around $0.2 million. Moreover, Citadel Securities LLC increased its share by 57360.0 to have a control over 57360.0 shares. And Geode Capital Management LLC raised its holdings to 35709.0 shares by acquiring 35709.0 shares or 0.57% of the stake.
Revelation Biosciences Inc (REVB) concluded trading on Wednesday at a closing price of $0.39, with 3.25 million shares of worth about $1.27 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.47% during that period and On Wednesday, January 24 the price saw a gain of about 19.32%. Currently the company’s common shares owned by public are about 6.30M shares, out of which, 6.20M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 8 times over the past 12 months. They bought 51,500 shares in 2 of the transactions. In 6 selling transactions, insiders dumped 39,731 shares.
The company recently came buying 0.0 shares which brought its stake up to 0.57% of the company’s outstanding shares.
However, the stock later moved at a day high price of 0.4978, or with a gain of 19.32%. Stock saw a price change of -9.53% in past 5 days and over the past one month there was a price change of -30.88%. Year-to-date (YTD), REVB shares are showing a performance of -21.31% which decreased to -95.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $11.39 during that period. The average intraday trading volume for Revelation Biosciences Inc shares is 102.09K. The stock is currently trading -16.04% below its 20-day simple moving average (SMA20), while that difference is down -29.25% for SMA50 and it goes to -50.02% lower than SMA200.
Walleye Capital LLC acquired 0.39 million shares of Revelation Biosciences Inc having value of about $0.2 million. Data submitted at the U.S SEC by Walleye Capital LLC revealed that the firm now holds 82219.0 shares in the company valued at close to $32065.41, or have control over 26.60% stake in the company. Revelation Biosciences Inc (NASDAQ: REVB) currently have 6.30M outstanding shares and institutions hold larger chunk of about 15.23% of that. Holding of mutual funds in the company is about 1.14% while other institutional holders and individual stake holders have control over 14.57% and 0.66% of the stake respectively.
The stock has a current market capitalization of $2.48M and its 3Y-monthly beta is at 0.37. It has posted earnings per share of -$0.47 in the same period. It has Quick Ratio of 2.62 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for REVB, volatility over the week remained 29.34% while standing at 13.65% over the month.
Analysts are in expectations that Revelation Biosciences Inc (REVB) stock would likely to be making an EPS of -$0.46 in the current quarter, while forecast for next quarter EPS is -$0.48 and it is -$1.54 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.46 which is -$0.46 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.77 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 94.92% while it is estimated to decrease by -50.98% in next year.
